FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021932481> ?p ?o ?g. }

• W3021932481 abstract "Abstract Oncogenic NRAS mutations are highly prevalent in hematologic malignancies. In acute myeloid leukemia (AML), genetic analysis supports the hypothesis that NRAS mutations cooperate with antecedent molecular lesions in leukemogenesis. Furthermore, NRAS mutations identified at diagnosis may disappear at relapse, raising questions regarding the potential clinical benefits of inhibiting oncogenic N-Ras in AML. To directly investigate the consequences of Nras inactivation in normal hematopoiesis, we used the Mx1-Cre transgene to inactivate a conditional mutant Nras allele and analyzed hematopoiesis and hematopoietic stem and progenitor cells (HSPC) under normal and stressed conditions. We show that HSPCs lacking Nras expression are functionally equivalent to normal HSPCs in the adult mouse. Importantly, shRNA-mediated knockdown in human AML cell lines and primary mouse leukemias with oncogenic NRAS/Nras mutations revealed dependence on continued oncogene expression in vitro and in vivo. Next, we interrogated the functional consequences of pharmacologic inhibition of the canonical Ras effector pathways, the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways,alone and in combination. Recipient mice transplanted with five independent primary mouse AMLs generated by infecting NrasG12D “knock in” mice with the MOL4070LTR retrovirus (Li et al, Blood 2011; 117:2022) were treated with the allosteric MEK inhibitors PD0325901 (PD901) or trametinib or the PI3K inhibitor GDC-0941. Both MEK inhibitors significantly prolonged survival and reduced proliferation and blast colony formation, but did not induce apoptosis, differentiation, or promote clonal evolution. PI3K inhibition alone was ineffective in vivo and combinations of MEK and PI3K inhibitors were no better than MEK inhibition alone. All mice ultimately succumbed from progressive leukemia. These data, along with observations that Nras is dispensable for normal hematopoiesis, validate oncogenic N-Ras signaling as a therapeutic target in AML and support testing combination regimens that include MEK inhibitors in leukemias harboring NRAS mutations. Disclosures No relevant conflicts of interest to declare." @default.
• W3021932481 created "2020-05-13" @default.
• W3021932481 creator A5006266700 @default.
• W3021932481 creator A5019784405 @default.
• W3021932481 creator A5023734568 @default.
• W3021932481 creator A5025451142 @default.
• W3021932481 creator A5035774267 @default.
• W3021932481 creator A5040397780 @default.
• W3021932481 creator A5044476766 @default.
• W3021932481 creator A5053780153 @default.
• W3021932481 creator A5066630813 @default.
• W3021932481 creator A5071088218 @default.
• W3021932481 creator A5075995627 @default.
• W3021932481 creator A5076651825 @default.
• W3021932481 creator A5091324982 @default.
• W3021932481 date "2014-12-06" @default.
• W3021932481 modified "2023-09-29" @default.
• W3021932481 title "Preclinical Efficacy of MEK Inhibition in Nras Mutant Acute Myeloid Leukemia" @default.
• W3021932481 cites W1965972240 @default.
• W3021932481 cites W1973297092 @default.
• W3021932481 cites W1977420876 @default.
• W3021932481 cites W1982791774 @default.
• W3021932481 cites W1984209370 @default.
• W3021932481 cites W1994491427 @default.
• W3021932481 cites W2007117393 @default.
• W3021932481 cites W2009333774 @default.
• W3021932481 cites W2012753533 @default.
• W3021932481 cites W2029754521 @default.
• W3021932481 cites W2032078881 @default.
• W3021932481 cites W2035049668 @default.
• W3021932481 cites W2038970416 @default.
• W3021932481 cites W2042612710 @default.
• W3021932481 cites W2043216151 @default.
• W3021932481 cites W2043282329 @default.
• W3021932481 cites W2043398720 @default.
• W3021932481 cites W2050206485 @default.
• W3021932481 cites W2052600649 @default.
• W3021932481 cites W2055521874 @default.
• W3021932481 cites W2056960087 @default.
• W3021932481 cites W2076031927 @default.
• W3021932481 cites W2077330278 @default.
• W3021932481 cites W2077730236 @default.
• W3021932481 cites W2080719056 @default.
• W3021932481 cites W2082710561 @default.
• W3021932481 cites W2083398319 @default.
• W3021932481 cites W2096046981 @default.
• W3021932481 cites W2101590448 @default.
• W3021932481 cites W2116796524 @default.
• W3021932481 cites W2124789340 @default.
• W3021932481 cites W2128339707 @default.
• W3021932481 cites W2147338626 @default.
• W3021932481 cites W2148965443 @default.
• W3021932481 cites W2164227047 @default.
• W3021932481 cites W2167348350 @default.
• W3021932481 cites W2171383975 @default.
• W3021932481 cites W2414010751 @default.
• W3021932481 doi "https://doi.org/10.1182/blood.v124.21.3753.3753" @default.
• W3021932481 hasPublicationYear "2014" @default.
• W3021932481 type Work @default.
• W3021932481 sameAs 3021932481 @default.
• W3021932481 citedByCount "0" @default.
• W3021932481 crossrefType "journal-article" @default.
• W3021932481 hasAuthorship W3021932481A5006266700 @default.
• W3021932481 hasAuthorship W3021932481A5019784405 @default.
• W3021932481 hasAuthorship W3021932481A5023734568 @default.
• W3021932481 hasAuthorship W3021932481A5025451142 @default.
• W3021932481 hasAuthorship W3021932481A5035774267 @default.
• W3021932481 hasAuthorship W3021932481A5040397780 @default.
• W3021932481 hasAuthorship W3021932481A5044476766 @default.
• W3021932481 hasAuthorship W3021932481A5053780153 @default.
• W3021932481 hasAuthorship W3021932481A5066630813 @default.
• W3021932481 hasAuthorship W3021932481A5071088218 @default.
• W3021932481 hasAuthorship W3021932481A5075995627 @default.
• W3021932481 hasAuthorship W3021932481A5076651825 @default.
• W3021932481 hasAuthorship W3021932481A5091324982 @default.
• W3021932481 hasConcept C104317684 @default.
• W3021932481 hasConcept C109159458 @default.
• W3021932481 hasConcept C184235292 @default.
• W3021932481 hasConcept C201750760 @default.
• W3021932481 hasConcept C203014093 @default.
• W3021932481 hasConcept C21790070 @default.
• W3021932481 hasConcept C2778461978 @default.
• W3021932481 hasConcept C2778472372 @default.
• W3021932481 hasConcept C2778729363 @default.
• W3021932481 hasConcept C2779282312 @default.
• W3021932481 hasConcept C2781187634 @default.
• W3021932481 hasConcept C2781249067 @default.
• W3021932481 hasConcept C28328180 @default.
• W3021932481 hasConcept C501734568 @default.
• W3021932481 hasConcept C502942594 @default.
• W3021932481 hasConcept C54355233 @default.
• W3021932481 hasConcept C57074206 @default.
• W3021932481 hasConcept C62478195 @default.
• W3021932481 hasConcept C86554907 @default.
• W3021932481 hasConcept C86803240 @default.
• W3021932481 hasConcept C95444343 @default.
• W3021932481 hasConceptScore W3021932481C104317684 @default.
• W3021932481 hasConceptScore W3021932481C109159458 @default.
• W3021932481 hasConceptScore W3021932481C184235292 @default.
• W3021932481 hasConceptScore W3021932481C201750760 @default.

• next